Patrick Doyle

Patrick Doyle has extensive experience in the biotechnology and pharmaceutical industry. Patrick is currently serving as the Chief Executive Officer at KBio since June 2021. Prior to this, from September 2018 to May 2021, they held the position of CEO at Stelexis Therapeutics. From December 2017 to September 2018, Patrick worked as a Consultant at Stelexis.

Patrick has also served in various leadership roles at different companies. Patrick worked as the Chief Business Officer at Synthorx Inc, where they played a significant role in developing business strategies, expanding the company's pipeline, and securing financing. Before that, they served as the President and Member of the Board of Directors at KineMed, Inc. Additionally, Patrick served as the Chief Executive Officer at Kareus Therapeutics, where they spearheaded partnerships and financing efforts and successfully concluded Phase I trials.

Their previous roles also include Chief Executive Officer at Syntaxin Ltd, Chief Business Officer at CymaBay Therapeutics, and Vice-President Pre-Clinical Partnering at Hoffmann-La Roche.

Patrick Doyle has demonstrated strong leadership skills and a track record of strategic planning, business development, and financial management throughout their career in the biotechnology and pharmaceutical industry.

Patrick Doyle attended the University of Sunderland from 1983 to 1986, where they received a Bachelor of Science degree in Pharmacology. Patrick then pursued further education at the University of Geneva from 1990 to 1995, specializing in Central Nervous System (CNS) Function. In 2009, Patrick enrolled at the University of London to pursue a Master at Laws degree, which they are expected to complete in 2022.